ENGN Stock Overview
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
enGene Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.52 |
| 52 Week High | US$47.17 |
| 52 Week Low | US$6.69 |
| Beta | -0.49 |
| 1 Month Change | -10.32% |
| 3 Month Change | 83.10% |
| 1 Year Change | 37.76% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 47.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| ENGN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.2% | 1.3% | 3.3% |
| 1Y | 37.8% | 3.0% | 25.0% |
Return vs Industry: ENGN exceeded the US Biotechs industry which returned 3.4% over the past year.
Return vs Market: ENGN exceeded the US Market which returned 25.8% over the past year.
Price Volatility
| ENGN volatility | |
|---|---|
| ENGN Average Weekly Movement | 34.2% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ENGN's share price has been volatile over the past 3 months.
Volatility Over Time: ENGN's weekly volatility has increased from 29% to 34% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2023 | 32 | Jason Hanson | www.engene.com |
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
enGene Holdings Inc. Fundamentals Summary
| ENGN fundamental statistics | |
|---|---|
| Market cap | US$640.35m |
| Earnings (TTM) | -US$106.80m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.0x
P/E RatioIs ENGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ENGN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$106.80m |
| Earnings | -US$106.80m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.42 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 36.1% |
How did ENGN perform over the long term?
See historical performance and comparison